Navigation Links
New Rhinosinusitis Clinical Trials Guidance Developed

More than 30 million Americans can attest that rhinosinusitis – an often recurring combination of congestion, discolored nasal discharge//, cough, and headache – seriously affects their quality of life.

A group of 25 physicians from five national medical societies has collaborated to design the first clinical trial guidelines for researchers working to find the most effective treatments for rhinosinusitis.

The U.S. Food and Drug Administration (FDA) has issued specific guidance documents for designing clinical trials of certain diseases, including acute bacterial sinusitis, but there has not been a guidance document put forth for chronic rhinosinusitis clinical trials. “Rhinosinusitis: Developing Guidance for Clinical Trials,” bridges this gap and offers researchers specific recommendations for rhinosinusitis clinical trials pertaining to acute bacterial rhinosinusitis, chronic rhinosinusitis with or without nasal polyps, and allergic fungal rhinosinusitis.

The guidelines will be published in November 2006 in a supplement of the American Academy of Allergy, Asthma and Immunology’s (AAAAI) Journal of Allergy and Clinical Immunology (JACI) and in the American Academy of Otolaryngology – Head and Neck Surgery/Foundation’s (AAO-HNS/F) white journal, Otolaryngology – Head and Neck Surgery. The corresponding author is Eli O. Meltzer, MD, Co-Director, Allergy and Asthma Medical Group and Research Center, San Diego, CA.

“The goal of the Rhinosinusitis Initiative has been to provide researchers with the needed methodologies which will promote better clinical studies that can lead to improved patient care,” Meltzer said.

Key components of the guidance include:
?Reviewing FDA’s role in drug trials.
?Presenting guidance for rhinosinusitis clinical trials of antimicrobials, anti-inflammatory treatment, and symptom reliever or mediator blocker treatments.
?Recommending scoring instruments for symptoms, rad iographs, endoscopic testing, and quality of life assessment.
?Recommending techniques for quantifying microbiologic factors, assessing inflammatory indices, and statistically measuring outcomes.

“Rhinosinusitis: Developing Guidance for Clinical Trials” offers a comprehensive list of rhinosinusitis clinical trial components ranging from the title of the trial, to study design, objectives and safety assessments.

The five societies involved in the collaboration include: the American Academy of Allergy, Asthma and Immunology (AAAAI); the American Academy of Otolaryngic Allergy (AAOA); the American Academy of Otolaryngology – Head and Neck Surgery/Foundation (AAO-HNS/F); the American College of Allergy, Asthma and Immunology (ACAAI); and the American Rhinologic Society (ARS).

This is the group’s second collaboration. Its original document, “Rhinosinusitis: Establishing Definitions for Clinical Research and Patient Care,” was published concurrently in the December 2004 editions of the JACI and OTO-HNS and can be found at http://journal.entnet.org. The document, which led to “Rhinosinusitis: Developing Guidance for Clinical Trials,” was a catalyst for further research on this disease. The participants in the effort agree that promoting more research on both acute and chronic rhinosinusitis is essential, and a better understanding of the cause of these diseases is needed.

Soure-Newswise
SRM
'"/>




Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
8. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
9. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
10. Cancer Clinical Research in India
11. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology: